Genmab — Maj 2019
-
Det er ikke lang tid siden af Danske Bank varmt anbefalede sundhedsaktier.
-
Bevis for Ganske Blank
-
Claus Johansen fra Danske Bank har været i USA og har udover JNJ også større investorer. Disse investorer skrækslagne over hvad Donald Trump, Bernie Sanders og co. kan finde på af initiativer til lavere medicin priser. Hvis det er en ting begge fløje er enige om, så er det dette. Så de store kasser vil nok være tilbageholdende til Pharma/biotek under valgkampen
-
POTENT ANTI-TUMOR ACTIVITY OF DUOBODY
-CD3XCD20 IN PRECLINICAL MODELS IN VITRO AND IN VIVO https://learningcenter.ehaweb.org/eha/2019/24th/266918/ida.hiemstra.potent.anti-tumor.activity.of.duobody-cd3xcd20.in.preclinical.html?f=listing%3D0*browseby%3D8*sortby%3D1*search%3Dcd20%2Bcd3 -
Luk i dagens højeste.
-
Jeg ved ikke helt om den er listet her,Bryan Garnier :GENMAB: SC Darzalex should make isatuximab obsolete | BUY | DKK1300(+17%)
GENMAB - BUY | DKK1300(+17%)
SC Darzalex should make isatuximab obsoleteIsatuximab’s data show no clear superiority over Dara
Subcutaneous Darzalex: a better Darzalex in every way -
-
After discount row, NICE finally says yes to first line Revlimid https://www.pmlive.com/pharma_news/after_discount_row,_nice_finally_says_yes_to_first_line_revlimid_1288450
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind